Actinium Pharmaceuticals, Inc.

ATNM

HealthcareBiotechnologyAMEX

$1.29

Market Cap: $40.47M

Actinium Pharmaceuticals, Inc. (ATNM) Valuation Summary

Updated Apr 6, 2026 22:24

Model	Range	Fair Value	Upside
▸ Discounted Cash Flow
Revenue DCF 5Y	$82.56 – $472.79	$85.35	+7730.2%
Revenue DCF 10Y	—	N/A	—
▸ Trading Multiples
EV/Revenue	$1.50 – $1.50	$5.53	+406.9%

Valuation History

DCF Analysis

Actinium Pharmaceuticals, Inc. (ATNM) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$85.35

Market Price

$1.29

Upside / Downside

+6516.3%

Verdict

Undervalued

Using a Revenue DCF model with operating margin convergence from -40274.4% to a target of 13.3% over 5 years, discounted at a WACC of 8.6%, Actinium Pharmaceuticals, Inc. (ATNM) has an intrinsic value of $85.35 per share (range: $82.56 – $472.79).

Key Assumptions

Current Operating Margin

-40274.4%

Target Operating Margin

13.3%

WACC

8.6%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

87.9%

Target CapEx/Rev

750.5%

D&A/Revenue

500.3%

Tax Rate

21.0%

Operating margin fades linearly from the current level to the industry target over the 5-year projection. CapEx intensity fades from the historical average to a maintenance level (D&A × 1.5). Tax is only applied when operating income is positive (NOL shield).

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	13	14247.8%	-32216.9%	-4,160	-4,160	65	(28)	-364	-3,760	-3,607
2027	39	200.3%	-24159.3%	-9,369	-9,369	194	(137)	-730	-8,582	-7,580
2028	12	-68.3%	-16101.8%	-1,979	-1,979	61	(60)	747	-2,725	-2,215
2029	70	469.0%	-8044.2%	-5,626	-5,626	350	(432)	-1,626	-4,082	-3,055
2030	132	88.7%	13.3%	18	14	660	(990)	-1,750	1,434	988

Enterprise Value Bridge

Sum of PV(FCFF)-15,470

Terminal Value (Gordon Growth at 3.0%)26,247

PV of Terminal Value18,086

Enterprise Value2,616

(–) Net Debt-46

Equity Value2,663

(÷) Shares Outstanding31

Fair Value per Share$85.35

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
6.6%	$464	$466	$468	$471	$473
7.6%	$230	$231	$233	$235	$237
8.6%	$83	$84	$85	$87	$88
9.6%	$-17	$-16	$-15	$-14	$-12
10.6%	$-88	$-87	$-86	$-85	$-84

Current price: $1.29. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at -2821.5% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$5.53

Market Price

$1.29

Upside / Downside

+328.3%

Verdict

Undervalued

Using the industry peer median EV/Revenue multiple (trailing + forward), Actinium Pharmaceuticals, Inc. (ATNM) has a fair value of $5.53 based on 2 comparable companies in the Biotechnology industry.

EV/Revenue Valuation — Biotechnology

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Actinium Pharmaceuticals, Inc.ATNM	40	-67.3x	-0.5x
Kezar Life Sciences, Inc.KZR	54	5.4x	9.4x
Tvardi Therapeutics, Inc.TVRD	28	4.8x	29.6x
Industry Median		5.1x	19.5x
(*) Revenue		0	13
= Enterprise Value		0	252
(-) Net Debt		-46	-46
Equity Value		47	298
(/) Outstanding shares		31	31
Fair Price		$1	$10

Selected Fair Value (avg of trailing + forward)

$5.53

+328.3%

Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.

Model

Range

Fair Value

Upside

▸ Discounted Cash Flow

Revenue DCF 5Y

$82.56 – $472.79

$85.35

+7730.2%

Revenue DCF 10Y

—

N/A

—

▸ Trading Multiples

EV/Revenue

$1.50 – $1.50

$5.53

+406.9%

DCF Analysis

Actinium Pharmaceuticals, Inc. (ATNM) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$85.35

Market Price

$1.29

Upside / Downside

+6516.3%

Verdict

Undervalued

Key Assumptions

Current Operating Margin

-40274.4%

Target Operating Margin

13.3%

WACC

8.6%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

87.9%

Target CapEx/Rev

750.5%

D&A/Revenue

500.3%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	13	14247.8%	-32216.9%	-4,160	-4,160	65	(28)	-364	-3,760	-3,607
2027	39	200.3%	-24159.3%	-9,369	-9,369	194	(137)	-730	-8,582	-7,580
2028	12	-68.3%	-16101.8%	-1,979	-1,979	61	(60)	747	-2,725	-2,215
2029	70	469.0%	-8044.2%	-5,626	-5,626	350	(432)	-1,626	-4,082	-3,055
2030	132	88.7%	13.3%	18	14	660	(990)	-1,750	1,434	988

Enterprise Value Bridge

Sum of PV(FCFF)-15,470

Terminal Value (Gordon Growth at 3.0%)26,247

PV of Terminal Value18,086

Enterprise Value2,616

(–) Net Debt-46

Equity Value2,663

(÷) Shares Outstanding31

Fair Value per Share$85.35

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
6.6%	$464	$466	$468	$471	$473
7.6%	$230	$231	$233	$235	$237
8.6%	$83	$84	$85	$87	$88
9.6%	$-17	$-16	$-15	$-14	$-12
10.6%	$-88	$-87	$-86	$-85	$-84

Current price: $1.29. Green = undervalued, Red = overvalued.

Working Capital Assumption

Trading Multiples

Fair Value

$5.53

Market Price

$1.29

Upside / Downside

+328.3%

Verdict

Undervalued

Using the industry peer median EV/Revenue multiple (trailing + forward), Actinium Pharmaceuticals, Inc. (ATNM) has a fair value of $5.53 based on 2 comparable companies in the Biotechnology industry.

EV/Revenue Valuation — Biotechnology

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Actinium Pharmaceuticals, Inc.ATNM	40	-67.3x	-0.5x
Kezar Life Sciences, Inc.KZR	54	5.4x	9.4x
Tvardi Therapeutics, Inc.TVRD	28	4.8x	29.6x
Industry Median		5.1x	19.5x
(*) Revenue		0	13
= Enterprise Value		0	252
(-) Net Debt		-46	-46
Equity Value		47	298
(/) Outstanding shares		31	31
Fair Price		$1	$10

Selected Fair Value (avg of trailing + forward)

$5.53

+328.3%